1
|
Liu S, Sun Q, Ren X. Novel strategies for cancer immunotherapy: counter-immunoediting therapy. J Hematol Oncol 2023; 16:38. [PMID: 37055849 PMCID: PMC10099030 DOI: 10.1186/s13045-023-01430-8] [Citation(s) in RCA: 32] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2023] [Accepted: 03/21/2023] [Indexed: 04/15/2023] Open
Abstract
The advent of immunotherapy has made an indelible mark on the field of cancer therapy, especially the application of immune checkpoint inhibitors in clinical practice. Although immunotherapy has proven its efficacy and safety in some tumors, many patients still have innate or acquired resistance to immunotherapy. The emergence of this phenomenon is closely related to the highly heterogeneous immune microenvironment formed by tumor cells after undergoing cancer immunoediting. The process of cancer immunoediting refers to the cooperative interaction between tumor cells and the immune system that involves three phases: elimination, equilibrium, and escape. During these phases, conflicting interactions between the immune system and tumor cells result in the formation of a complex immune microenvironment, which contributes to the acquisition of different levels of immunotherapy resistance in tumor cells. In this review, we summarize the characteristics of different phases of cancer immunoediting and the corresponding therapeutic tools, and we propose normalized therapeutic strategies based on immunophenotyping. The process of cancer immunoediting is retrograded through targeted interventions in different phases of cancer immunoediting, making immunotherapy in the context of precision therapy the most promising therapy to cure cancer.
Collapse
Affiliation(s)
- Shaochuan Liu
- Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, 300060, Tianjin, China
- Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, 300060, Tianjin, China
- Key Laboratory of Cancer Immunology and Biotherapy, 300060, Tianjin, China
- Key Laboratory of Cancer Prevention and Therapy, 300060, Tianjin, China
- Tianjin's Clinical Research Center for Cancer, 300060, Tianjin, China
- Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, 300060, Tianjin, China
| | - Qian Sun
- Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, 300060, Tianjin, China.
- Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, 300060, Tianjin, China.
- Key Laboratory of Cancer Immunology and Biotherapy, 300060, Tianjin, China.
- Key Laboratory of Cancer Prevention and Therapy, 300060, Tianjin, China.
- Tianjin's Clinical Research Center for Cancer, 300060, Tianjin, China.
- Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, 300060, Tianjin, China.
| | - Xiubao Ren
- Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, 300060, Tianjin, China.
- Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, 300060, Tianjin, China.
- Key Laboratory of Cancer Immunology and Biotherapy, 300060, Tianjin, China.
- Key Laboratory of Cancer Prevention and Therapy, 300060, Tianjin, China.
- Tianjin's Clinical Research Center for Cancer, 300060, Tianjin, China.
- Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, 300060, Tianjin, China.
| |
Collapse
|
2
|
Jacobs ET, Martinez J, Batai K, Lance P, Trejo M, Saboda K, Cordova C, Chew W, Habila M, Chow HHS. Effect Modification of Selenium Supplementation by Intake and Serum Concentrations of Antioxidants on the Development of Metachronous Colorectal Adenoma. Nutr Cancer 2022; 75:552-561. [PMID: 36272100 PMCID: PMC9974806 DOI: 10.1080/01635581.2022.2135745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2022] [Accepted: 10/03/2022] [Indexed: 10/24/2022]
Abstract
BACKGROUND Selenium (Se) is a trace element that has been investigated as a potential chemopreventive agent for colorectal cancer. Dietary intake of other antioxidant nutrients may modify the effect of Se. OBJECTIVE We examined the association between intake and serum concentrations of retinol, β-carotene, β-cryptoxanthin, lycopene, lutein/zeaxanthin, and α- and γ-tocopherol and the development of metachronous colorectal adenoma, and if these nutrients modified the effect of Se. METHODS We conducted a prospective study of 1874 participants from the Se Trial with data for antioxidant intake, as well as a subcohort of 508 participants with serum biomarker concentrations. RESULTS Statistically significantly lower odds for the development of metachronous adenoma were observed for those participants in the highest tertile of intake for lutein/zeaxanthin compared to the lowest, with an OR (95% CI) of 0.72 (0.56-0.94). No effect modification for intake of any nutrient was observed. However, circulating concentrations of lycopene exhibited statistically significant effect modification of selenium supplementation (p < 0.06). CONCLUSION These findings show that intake and circulating concentrations of antioxidant nutrients were not consistently associated with reduced odds for the development of metachronous lesions, although blood concentrations of lycopene may modify the effect of selenium supplementation.
Collapse
Affiliation(s)
- Elizabeth T Jacobs
- University of Arizona Cancer Center, University of Arizona, Tucson, Arizona
- Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona
| | - Jessica Martinez
- University of Arizona Cancer Center, University of Arizona, Tucson, Arizona
| | - Ken Batai
- Department of Urology, University of Arizona College of Medicine, Tucson, Arizona
- Roswell Park Cancer Center, Buffalo, New York
| | - Peter Lance
- University of Arizona Cancer Center, University of Arizona, Tucson, Arizona
| | - Mario Trejo
- Fred Hutchinson Cancer Research Center, Seattle, Washington
| | - Kathylynn Saboda
- University of Arizona Cancer Center, University of Arizona, Tucson, Arizona
| | - Catherine Cordova
- University of Arizona Cancer Center, University of Arizona, Tucson, Arizona
| | - Wade Chew
- University of Arizona Cancer Center, University of Arizona, Tucson, Arizona
| | - Magdiel Habila
- Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona
| | - H-H Sherry Chow
- University of Arizona Cancer Center, University of Arizona, Tucson, Arizona
| |
Collapse
|
3
|
Vetter VM, Sommerer Y, Kalies CH, Spira D, Bertram L, Demuth I. Vitamin D supplementation is associated with slower epigenetic aging. GeroScience 2022; 44:1847-1859. [PMID: 35562603 PMCID: PMC9213628 DOI: 10.1007/s11357-022-00581-9] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2022] [Accepted: 04/26/2022] [Indexed: 11/21/2022] Open
Abstract
Adverse effects of low vitamin D level on mortality and morbidity are controversially discussed. Especially older people are at risk for vitamin D deficiency and therefore exposed to its potentially harmful consequences. A way of measuring differences in the biological age is through DNA methylation age (DNAm age) and its deviation from chronological age, DNAm age acceleration (DNAmAA). We previously reported on an association between vitamin D deficiency and higher 7-CpG DNAmAA in participants of the Berlin Aging Study II (BASE-II). In this study, we employ a quasi-interventional study design to assess the relationship between DNAmAA of five epigenetic clocks and vitamin D supplementation. Longitudinal data were available for 1,036 participants of BASE-II that were reexamined on average 7.4 years later in the GendAge study (mean age at follow-up: 75.6 years, SD = 3.8 years, age range: 64.9-94.1 years, 51.9% female). DNAmAA was estimated with the 7-CpG clock, Horvath's clock, Hannum's clock, PhenoAge, and GrimAge. Methylation data were obtained through methylation-sensitive single nucleotide primer extension (MS-SNuPE) or Illumina's Infinium "MethylationEPIC" array. Vitamin D-deficient participants who chose to start vitamin D supplementation after baseline examination showed a 2.6-year lower 7-CpG DNAmAA (p = 0.011) and 1.3-year lower Horvath DNAmAA (p = 0.042) compared to untreated and vitamin D-deficient participants. DNAmAA did not statistically differ between participants with successfully treated vitamin D deficiency and healthy controls (p > 0.16). Therefore, we conclude that intake of vitamin D supplement is associated with lower DNAmAA in participants with vitamin D deficiency.
Collapse
Affiliation(s)
- Valentin Max Vetter
- Biology of Aging Working Group, Department of Endocrinology and Metabolic Diseases (Including Division of Lipid Metabolism), Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353, Berlin, Germany
- Department of Psychology, Humboldt University Berlin, Berlin, Germany
| | - Yasmine Sommerer
- Lübeck Interdisciplinary Platform for Genome Analytics (LIGA), University of Lübeck, Lübeck, Germany
| | - Christian Humberto Kalies
- Biology of Aging Working Group, Department of Endocrinology and Metabolic Diseases (Including Division of Lipid Metabolism), Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353, Berlin, Germany
| | - Dominik Spira
- Biology of Aging Working Group, Department of Endocrinology and Metabolic Diseases (Including Division of Lipid Metabolism), Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353, Berlin, Germany
| | - Lars Bertram
- Lübeck Interdisciplinary Platform for Genome Analytics (LIGA), University of Lübeck, Lübeck, Germany
- Center for Lifespan Changes in Brain and Cognition (LCBC), Department of Psychology, University of Oslo, Oslo, Norway
| | - Ilja Demuth
- Biology of Aging Working Group, Department of Endocrinology and Metabolic Diseases (Including Division of Lipid Metabolism), Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
- BCRT - Berlin Institute of Health Center for Regenerative Therapies, Charité - Universitätsmedizin Berlin, Berlin, Germany.
- Biology of Aging Group, Lipid Clinic at the Interdisciplinary Metabolism Center, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
| |
Collapse
|
4
|
Calcium intake may explain the reduction of colorectal cancer odds by dietary selenium - a case-control study in Poland. BMC Nutr 2022; 8:22. [PMID: 35287753 PMCID: PMC8919630 DOI: 10.1186/s40795-022-00515-w] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2021] [Accepted: 02/28/2022] [Indexed: 12/05/2022] Open
Abstract
Background Colorectal cancer (CRC) has been placed among top three cancer sites in high income countries. Although there are several inconsistencies across studies it is widely accepted that diet contributes to approximately 70% of CRC. Several dietary factors have been investigated; however, the knowledge about the role of trace elements and their interplay with other dietary factors in CRC odds is limited. The aim of the study was to estimate the odds ratio of colorectal cancer associated with the content of selenium in diet, and to check whether dietary calcium is a modifier of selenium effect in the population characterized by low selenium intake. Methods Face-to-face interviews were used to gather data on dietary habits (by 148-item semi-quantitative food frequency questionnaire) and covariates among 683 histologically confirmed incident colorectal cancer cases and 759 hospital-based controls in a case-control study. Data was collected in a period between 2000 and 2012. Setting: Lesser Poland, Central Europe. Logistic regression models were used to assess the role of dietary selenium intake and calcium-selenium interaction in colorectal cancer odds. Results After the adjustment for several covariates dietary selenium was associated with the decrease of colorectal cancer odds by 8% (OR = 0.92, 95%CI: 0.84–0.99 for every 10μg Se/day increase). In individuals with lower (< 1000 mg/day) calcium content the odds of colorectal cancer was decreased by 13%(for every 10μg Se/day) and by 44% and 66% depending on the categories of selenium intake (60 to < 80 μg/day and ≥ 80 μg/day, respectively). The effect of dietary selenium was modified by dietary calcium (p for interaction < .005). Conclusions The study has shown a beneficial effect of dietary selenium for colorectal cancer and a modification effect of dietary calcium in a population characterized by lower levels of selenium intake. The results provide the basis for well-planned controlled trials to confirm the findings. Supplementary Information The online version contains supplementary material available at 10.1186/s40795-022-00515-w.
Collapse
|
5
|
Angelé-Martínez C, Goncalves LCP, Premi S, Augusto FA, Palmatier MA, Amar SK, Brash DE. Triplet-Energy Quenching Functions of Antioxidant Molecules. Antioxidants (Basel) 2022; 11:antiox11020357. [PMID: 35204239 PMCID: PMC8868474 DOI: 10.3390/antiox11020357] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2021] [Revised: 02/01/2022] [Accepted: 02/08/2022] [Indexed: 01/27/2023] Open
Abstract
UV-like DNA damage is created in the dark by chemiexcitation, in which UV-activated enzymes generate reactive oxygen and nitrogen species that create a dioxetane on melanin. Thermal cleavage creates an electronically excited triplet-state carbonyl whose high energy transfers to DNA. Screening natural compounds for the ability to quench this energy identified polyenes, polyphenols, mycosporine-like amino acids, and related compounds better known as antioxidants. To eliminate false positives such as ROS and RNS scavengers, we then used the generator of triplet-state acetone, tetramethyl-1,2-dioxetane (TMD), to excite the triplet-energy reporter 9,10-dibromoanthracene-2-sulfonate (DBAS). Quenching measured as reduction in DBAS luminescence revealed three clusters of 50% inhibitory concentration, ~50 μM, 200–500 μM, and >600 μM, with the former including sorbate, ferulic acid, and resveratrol. Representative triplet-state quenchers prevented chemiexcitation-induced “dark” cyclobutane pyrimidine dimers (dCPD) in DNA and in UVA-irradiated melanocytes. We conclude that (i) the delocalized pi electron cloud that stabilizes the electron-donating activity of many common antioxidants allows the same molecule to prevent an electronically excited species from transferring its triplet-state energy to targets such as DNA and (ii) the most effective class of triplet-state quenchers appear to operate by energy diversion instead of electron donation and dissipate that energy by isomerization.
Collapse
Affiliation(s)
- Carlos Angelé-Martínez
- Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT 06520-8040, USA; (C.A.-M.); (L.C.P.G.); (S.P.); (F.A.A.); (M.A.P.); (S.K.A.)
| | - Leticia Christina Pires Goncalves
- Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT 06520-8040, USA; (C.A.-M.); (L.C.P.G.); (S.P.); (F.A.A.); (M.A.P.); (S.K.A.)
| | - Sanjay Premi
- Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT 06520-8040, USA; (C.A.-M.); (L.C.P.G.); (S.P.); (F.A.A.); (M.A.P.); (S.K.A.)
| | - Felipe A. Augusto
- Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT 06520-8040, USA; (C.A.-M.); (L.C.P.G.); (S.P.); (F.A.A.); (M.A.P.); (S.K.A.)
- Departamento de Química Fundamental, Instituto de Química, Universidade de São Paulo, São Paulo 05508-900, SP, Brazil
| | - Meg A. Palmatier
- Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT 06520-8040, USA; (C.A.-M.); (L.C.P.G.); (S.P.); (F.A.A.); (M.A.P.); (S.K.A.)
| | - Saroj K. Amar
- Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT 06520-8040, USA; (C.A.-M.); (L.C.P.G.); (S.P.); (F.A.A.); (M.A.P.); (S.K.A.)
| | - Douglas E. Brash
- Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT 06520-8040, USA; (C.A.-M.); (L.C.P.G.); (S.P.); (F.A.A.); (M.A.P.); (S.K.A.)
- Department of Dermatology, Yale School of Medicine, New Haven, CT 06520-8059, USA
- Yale Cancer Center, Yale School of Medicine, New Haven, CT 06520-8028, USA
- Correspondence:
| |
Collapse
|
6
|
Yang CS, Chen XL. Research on esophageal cancer: With personal perspectives from studies in China and Kenya. Int J Cancer 2021; 149:264-276. [PMID: 33270917 PMCID: PMC8141013 DOI: 10.1002/ijc.33421] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2020] [Revised: 11/17/2020] [Accepted: 11/18/2020] [Indexed: 12/11/2022]
Abstract
The most common form of esophageal cancer (EC), esophageal squamous cell carcinoma (ESCC), is prevalent in many unindustrialized societies, among people with lower socioeconomic status and those who frequently use tobacco and alcohol. In some areas, ESCC mortality ranked top among all cancer. In this review, we begin with discussions of the extensive research on EC in Linxian in northern China that started 60 years ago and the recent studies in Kenya from our personal perspectives. Based on the results obtained from these studies and information from the literature, we summarize our current understanding about the risk factors for ESCC including lifestyle factors (smoking, alcohol, consumption of food and beverages at high temperature and other unhealthy habits), poor diet and nutritional insufficiencies and genetic susceptibility. Elimination or minimization of these environmental risk factors, as well as early detection and treatment of precancerous lesions, would be effective means for the prevention of ESCC. Current knowledge of molecular alterations in ESCC (gene mutations, hypermethylation and amplification or overexpression), as well as treatment of ESCC and the potential of targeted therapy, are also discussed. Finally, we propose effective approaches for the prevention of ESCC by adapting a healthy lifestyle, including a healthy diet that would also prevent other diseases. Community outreach, public education and international collaboration are important for achieving this public health goal.
Collapse
Affiliation(s)
- Chung S. Yang
- Department of Chemical BiologyErnest Mario School of Pharmacy, Rutgers, The State University of New JerseyPiscatawayNew JerseyUSA
| | - Xiaoxin Luke Chen
- Cancer Research Program, Julius L. Chambers Biomedical Biotechnology Research Institute, North Carolina Central UniversityDurhamNorth CarolinaUSA
| |
Collapse
|
7
|
Batai K, Trejo MJ, Chen Y, Kohler LN, Lance P, Ellis NA, Cornelis MC, Chow HHS, Hsu CH, Jacobs ET. Genome-Wide Association Study of Response to Selenium Supplementation and Circulating Selenium Concentrations in Adults of European Descent. J Nutr 2020; 151:293-302. [PMID: 33382417 PMCID: PMC7849979 DOI: 10.1093/jn/nxaa355] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2020] [Revised: 07/31/2020] [Accepted: 10/14/2020] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND Selenium (Se) is a trace element that has been linked to many health conditions. Genome-wide association studies (GWAS) have identified variants for blood and toenail Se levels, but no GWAS has been conducted to date on responses to Se supplementation. OBJECTIVES A GWAS was performed to identify the single nucleotide polymorphisms (SNPs) associated with changes in Se concentrations after 1 year of supplementation. A GWAS of basal plasma Se concentrations at study entry was conducted to evaluate whether SNPs for Se responses overlap with SNPs for basal Se levels. METHODS A total of 428 participants aged 40-80 years of European descent from the Selenium and Celecoxib Trial (Sel/Cel Trial) who received daily supplementation with 200 µg of selenized yeast were included for the GWAS of responses to supplementation. Plasma Se concentrations were measured from blood samples collected at the time of recruitment and after 1 year of supplementation. Linear regression analyses were performed to assess the relationship between each SNP and changes in Se concentrations. We further examined whether the identified SNPs overlapped with those related to basal Se concentrations. RESULTS No SNP was significantly associated with changes in Se concentration at a genome-wide significance level. However, rs56856693, located upstream of the NEK6, was nominally associated with changes in Se concentrations after supplementation (P = 4.41 × 10-7), as were 2 additional SNPs, rs11960388 and rs6887869, located in the dimethylglycine dehydrogenase (DMGDH)/betaine-homocysteine S-methyltransferase (BHMT) region (P = 0.01). Alleles of 2 SNPs in the DMGDH/BHMT region associated with greater increases in Se concentrations after supplementation were also strongly associated with higher basal Se concentrations (P = 8.67 × 10-8). CONCLUSIONS This first GWAS of responses to Se supplementation in participants of European descent from the Sel/Cel Trial suggests that SNPs in the NEK6 and DMGDH/BHMT regions influence responses to supplementation.
Collapse
Affiliation(s)
- Ken Batai
- Address correspondence to KB (E-mail: )
| | - Mario J Trejo
- Department of Epidemiology and Biostatistics, University of Arizona, Tucson, AZ, USA
| | - Yuliang Chen
- Department of Epidemiology and Biostatistics, University of Arizona, Tucson, AZ, USA
| | - Lindsay N Kohler
- Department of Health Promotion Science, University of Arizona, Tucson, AZ, USA
| | - Peter Lance
- University of Arizona Cancer Center, Tucson, AZ, USA,Department of Cellular and Molecular Medicine, University of Arizona, Tucson, AZ, USA
| | - Nathan A Ellis
- Department of Cellular and Molecular Medicine, University of Arizona, Tucson, AZ, USA
| | - Marilyn C Cornelis
- Department of Preventive Medicine, Northwestern University, Chicago, IL, USA
| | - H-H Sherry Chow
- University of Arizona Cancer Center, Tucson, AZ, USA,Department of Medicine, College of Medicine, University of Arizona, Tucson, AZ, USA
| | - Chiu-Hsieh Hsu
- Department of Epidemiology and Biostatistics, University of Arizona, Tucson, AZ, USA
| | - Elizabeth T Jacobs
- Department of Epidemiology and Biostatistics, University of Arizona, Tucson, AZ, USA,University of Arizona Cancer Center, Tucson, AZ, USA
| |
Collapse
|
8
|
Rowles JL, Smith JW, Applegate CC, Miller RJ, Wallig MA, Kaur A, Sarol JN, Musaad S, Clinton SK, O'Brien WD, Erdman JW. Dietary Tomato or Lycopene Do Not Reduce Castration-Resistant Prostate Cancer Progression in a Murine Model. J Nutr 2020; 150:1808-1817. [PMID: 32369574 PMCID: PMC7330476 DOI: 10.1093/jn/nxaa107] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2020] [Revised: 03/05/2020] [Accepted: 03/26/2020] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Dietary tomato products or lycopene protect against prostate carcinogenesis, but their impact on the emergence of castration-resistant prostate cancer (CRPC) is unknown. OBJECTIVE We hypothesized that tomato or lycopene products would reduce the emergence of CRPC. METHODS Transgenic adenocarcinoma of the mouse prostate (TRAMP) mice were castrated at 12-13 wk and the emergence of CRPC was monitored by ultrasound in each study. In Study 1, TRAMP mice (n = 80) were weaned onto an AIN-93G-based control diet (Con-L, n = 28), a 10% tomato powder diet (TP-L, 10% lyophilized w/w, n = 26), or a control diet followed by a tomato powder diet after castration (TP-Int1, n = 26). In Study 2, TRAMP mice (n = 85) were randomized onto a control diet with placebo beadlets (Con-Int, n = 29), a tomato diet with placebo beadlets (TP-Int2, n = 29), or a control diet with lycopene beadlets (Lyc-Int, n = 27) following castration (aged 12 wk). Tumor incidence and growth were monitored by ultrasound beginning at an age of 10 wk. Mice were euthanized 4 wk after tumor detection or aged 30 wk if no tumor was detected. Tissue weights were compared by ANOVA followed by Dunnett's test. Tumor volumes were compared using generalized linear mixed model regression. RESULTS Ultrasound estimates for the in vivo tumor volume were strongly correlated with tumor weight at necropsy (R2 = 0.75 and 0.94, P <0.001 for both Studies 1 and 2, respectively). Dietary treatments after castration did not significantly impact cancer incidence, time to tumor detection, or final tumor weight. CONCLUSIONS In contrast to studies of de novo carcinogenesis in multiple preclinical models, tomato components had no significant impact on the emergence of CRPC in the TRAMP model. It is possible that specific mutant subclones of prostate cancer may continue to show some antiproliferative response to tomato components, but further studies are needed to confirm this.
Collapse
Affiliation(s)
- Joe L Rowles
- Division of Nutritional Sciences, University of Illinois at Urbana-Champaign, Urbana, IL, USA
| | - Joshua W Smith
- Division of Nutritional Sciences, University of Illinois at Urbana-Champaign, Urbana, IL, USA
| | - Catherine C Applegate
- Division of Nutritional Sciences, University of Illinois at Urbana-Champaign, Urbana, IL, USA
| | - Rita J Miller
- Department of Electrical and Computer Engineering, University of Illinois at Urbana-Champaign, Urbana, IL, USA
| | - Matthew A Wallig
- Division of Nutritional Sciences, University of Illinois at Urbana-Champaign, Urbana, IL, USA
- Department of Pathobiology, University of Illinois at Urbana-Champaign, Urbana, IL, USA
| | - Amandeep Kaur
- Interdisciplinary Health Sciences Institute, University of Illinois at Urbana-Champaign, Urbana, IL, USA
| | - Jesus N Sarol
- Interdisciplinary Health Sciences Institute, University of Illinois at Urbana-Champaign, Urbana, IL, USA
| | - Salma Musaad
- Interdisciplinary Health Sciences Institute, University of Illinois at Urbana-Champaign, Urbana, IL, USA
| | - Steven K Clinton
- Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
- Molecular Carcinogenesis and Chemoprevention Program, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
| | - William D O'Brien
- Division of Nutritional Sciences, University of Illinois at Urbana-Champaign, Urbana, IL, USA
- Department of Electrical and Computer Engineering, University of Illinois at Urbana-Champaign, Urbana, IL, USA
| | - John W Erdman
- Division of Nutritional Sciences, University of Illinois at Urbana-Champaign, Urbana, IL, USA
- Department of Food Science and Human Nutrition, University of Illinois at Urbana-Champaign, Urbana, USA
| |
Collapse
|
9
|
Csizmadi I, Lin PH, Freedland SJ. Vegetable Consumption and Progression of Prostate Cancer. JAMA 2020; 323:2529-2530. [PMID: 32573662 DOI: 10.1001/jama.2020.6729] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Affiliation(s)
- Ilona Csizmadi
- Center for Integrated Research in Cancer and Lifestyle, Cedars-Sinai Medical Center, Los Angeles, California
| | - Pao-Hwa Lin
- Department of Medicine, Duke University School of Medicine, Durham, North Carolina
| | - Stephen J Freedland
- Center for Integrated Research in Cancer and Lifestyle, Cedars-Sinai Medical Center, Los Angeles, California
| |
Collapse
|
10
|
Kiblawi R, Holowatyj AN, Gigic B, Brezina S, Geijsen AJMR, Ose J, Lin T, Hardikar S, Himbert C, Warby CA, Böhm J, Bours MJL, van Duijnhoven FJB, Gumpenberger T, Kok DE, Koole JL, van Roekel EH, Schrotz-King P, Ulvik A, Gsur A, Habermann N, Weijenberg MP, Ueland PM, Schneider M, Ulrich A, Ulrich CM, Playdon M. One-carbon metabolites, B vitamins and associations with systemic inflammation and angiogenesis biomarkers among colorectal cancer patients: results from the ColoCare Study. Br J Nutr 2020; 123:1187-1200. [PMID: 32019627 PMCID: PMC7425811 DOI: 10.1017/s0007114520000422] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
B vitamins involved in one-carbon metabolism have been implicated in the development of inflammation- and angiogenesis-related chronic diseases, such as colorectal cancer (CRC). Yet, the role of one-carbon metabolism in inflammation and angiogenesis among CRC patients remains unclear. The objective of this study was to investigate associations of components of one-carbon metabolism with inflammation and angiogenesis biomarkers among newly diagnosed CRC patients (n 238) in the prospective ColoCare Study, Heidelberg. We cross-sectionally analysed associations between twelve B vitamins and one-carbon metabolites and ten inflammation and angiogenesis biomarkers from pre-surgery serum samples using multivariable linear regression models. We further explored associations among novel biomarkers in these pathways with Spearman partial correlation analyses. We hypothesised that pyridoxal-5'-phosphate (PLP) is inversely associated with inflammatory biomarkers. We observed that PLP was inversely associated with C-reactive protein (CRP) (r -0·33, Plinear < 0·0001), serum amyloid A (SAA) (r -0·23, Plinear = 0·003), IL-6 (r -0·39, Plinear < 0·0001), IL-8 (r -0·20, Plinear = 0·02) and TNFα (r -0·12, Plinear = 0·045). Similar findings were observed for 5-methyl-tetrahydrofolate and CRP (r -0·14), SAA (r -0·14) and TNFα (r -0·15) among CRC patients. Folate catabolite acetyl-para-aminobenzoylglutamic acid (pABG) was positively correlated with IL-6 (r 0·27, Plinear < 0·0001), and pABG was positively correlated with IL-8 (r 0·21, Plinear < 0·0001), indicating higher folate utilisation during inflammation. Our data support the hypothesis of inverse associations between PLP and inflammatory biomarkers among CRC patients. A better understanding of the role and inter-relation of PLP and other one-carbon metabolites with inflammatory processes among colorectal carcinogenesis and prognosis could identify targets for future dietary guidance for CRC patients.
Collapse
Affiliation(s)
- Rama Kiblawi
- Division of Cancer Control and Population Sciences, Huntsman Cancer Institute, Salt Lake City, UT, USA
- Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA
- Medical Faculty, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany
| | - Andreana N. Holowatyj
- Division of Cancer Control and Population Sciences, Huntsman Cancer Institute, Salt Lake City, UT, USA
- Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Biljana Gigic
- Department of General, Visceral and Transplantation Surgery, University Hospital of Heidelberg, Germany
| | - Stefanie Brezina
- Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, Austria
| | - Anne J. M. R. Geijsen
- Division of Human Nutrition and Health, Wageningen University & Research, Wageningen, The Netherlands
| | - Jennifer Ose
- Division of Cancer Control and Population Sciences, Huntsman Cancer Institute, Salt Lake City, UT, USA
- Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA
| | - Tengda Lin
- Division of Cancer Control and Population Sciences, Huntsman Cancer Institute, Salt Lake City, UT, USA
- Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA
| | - Sheetal Hardikar
- Division of Cancer Control and Population Sciences, Huntsman Cancer Institute, Salt Lake City, UT, USA
- Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA
| | - Caroline Himbert
- Division of Cancer Control and Population Sciences, Huntsman Cancer Institute, Salt Lake City, UT, USA
- Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA
| | - Christy A. Warby
- Division of Cancer Control and Population Sciences, Huntsman Cancer Institute, Salt Lake City, UT, USA
- Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA
| | - Jürgen Böhm
- Division of Cancer Control and Population Sciences, Huntsman Cancer Institute, Salt Lake City, UT, USA
- Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA
| | - Martijn J. L. Bours
- Department of Epidemiology, GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands
| | | | - Tanja Gumpenberger
- Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, Austria
| | - Dieuwertje E. Kok
- Division of Human Nutrition and Health, Wageningen University & Research, Wageningen, The Netherlands
| | - Janna L. Koole
- Department of Epidemiology, GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands
| | - Eline H. van Roekel
- Department of Epidemiology, GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands
| | - Petra Schrotz-King
- Division of Preventive Oncology, German Cancer Research Center and National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany
| | | | - Andrea Gsur
- Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, Austria
| | - Nina Habermann
- Department of Genome Biology, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany
| | - Matty P. Weijenberg
- Department of Epidemiology, GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands
| | - Per Magne Ueland
- Bevital A/S, Bergen, Norway
- Department of Clinical Science, Pharmacology, University of Bergen, Bergen, Hordaland, Norway
| | - Martin Schneider
- Department of General, Visceral and Transplantation Surgery, University Hospital of Heidelberg, Germany
| | - Alexis Ulrich
- Department of General, Visceral and Transplantation Surgery, University Hospital of Heidelberg, Germany
| | - Cornelia M. Ulrich
- Division of Cancer Control and Population Sciences, Huntsman Cancer Institute, Salt Lake City, UT, USA
- Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA
| | - Mary Playdon
- Division of Cancer Control and Population Sciences, Huntsman Cancer Institute, Salt Lake City, UT, USA
- Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA
- Department of Nutrition and Integrative Physiology, University of Utah, Salt Lake City, USA
| |
Collapse
|
11
|
Simmonds LA, Sullivan TR, Skubisz M, Middleton PF, Best KP, Yelland LN, Quinlivan J, Zhou SJ, Liu G, McPhee AJ, Gibson RA, Makrides M. Omega-3 fatty acid supplementation in pregnancy-baseline omega-3 status and early preterm birth: exploratory analysis of a randomised controlled trial. BJOG 2020; 127:975-981. [PMID: 32034969 DOI: 10.1111/1471-0528.16168] [Citation(s) in RCA: 59] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/31/2020] [Indexed: 11/27/2022]
Abstract
OBJECTIVE To identify a polyunsaturated fatty acid (PUFA) biomarker able to detect which women with singleton pregnancies are most likely to benefit from omega-3 supplementation to reduce their risk of early preterm birth. DESIGN Exploratory analysis of a randomised controlled trial. SETTING Six Australian hospitals. POPULATION Women with a singleton pregnancy enrolled in the ORIP trial. METHODS Using maternal capillary whole blood collected ~14 weeks' gestation, the fatty acids in total blood lipids were quantified using gas chromatography. Interaction tests examined whether baseline PUFA status modified the effect of omega-3 supplementation on birth outcomes. MAIN OUTCOME MEASURE Early preterm birth (<34 weeks' gestation). RESULTS A low total omega-3 PUFA status in early pregnancy was associated with a higher risk of early preterm birth. Among women with a total omega-3 status ≤4.1% of total fatty acids, omega-3 supplementation substantially reduced the risk of early preterm birth compared with control (0.73 versus 3.16%; relative risk = 0.23, 95% confidence interval [CI] 0.07-0.79). Conversely, women with higher total omega-3 status in early pregnancy were at lower risk of early preterm birth. Supplementing women with a baseline status above 4.9% increased early preterm birth (2.20 versus 0.97%; relative risk = 2.27, 95% CI 1.13-4.58). CONCLUSIONS Women with singleton pregnancies and low total omega-3 PUFA status early in pregnancy have an increased risk of early preterm birth and are most likely to benefit from omega-3 supplementation to reduce this risk. Women with higher total omega-3 status are at lower risk and additional omega-3 supplementation may increase their risk. TWEETABLE ABSTRACT Low total omega-3 fat status helps identify which women benefit from extra omega-3 to reduce early prematurity.
Collapse
Affiliation(s)
- L A Simmonds
- SAHMRI Women and Kids, South Australian Health and Medical Research Institute, Adelaide, SA, Australia
| | - T R Sullivan
- SAHMRI Women and Kids, South Australian Health and Medical Research Institute, Adelaide, SA, Australia
| | - M Skubisz
- SAHMRI Women and Kids, South Australian Health and Medical Research Institute, Adelaide, SA, Australia.,Department of Obstetrics and Gynaecology, Women's and Children's Hospital, North Adelaide, SA, Australia
| | - P F Middleton
- SAHMRI Women and Kids, South Australian Health and Medical Research Institute, Adelaide, SA, Australia.,School of Medicine, The University of Adelaide, Adelaide, SA, Australia
| | - K P Best
- SAHMRI Women and Kids, South Australian Health and Medical Research Institute, Adelaide, SA, Australia.,School of Medicine, The University of Adelaide, Adelaide, SA, Australia
| | - L N Yelland
- SAHMRI Women and Kids, South Australian Health and Medical Research Institute, Adelaide, SA, Australia.,School of Public Health, The University of Adelaide, Adelaide, SA, Australia
| | - J Quinlivan
- The Institute of Health Research, University of Notre Dame, Fremantle, WA, Australia
| | - S J Zhou
- The School of Agriculture, Food and Wine, The University of Adelaide, Adelaide, SA, Australia
| | - G Liu
- SAHMRI Women and Kids, South Australian Health and Medical Research Institute, Adelaide, SA, Australia.,The School of Agriculture, Food and Wine, The University of Adelaide, Adelaide, SA, Australia
| | - A J McPhee
- SAHMRI Women and Kids, South Australian Health and Medical Research Institute, Adelaide, SA, Australia.,Neonatal Services, Women's and Children's Hospital, North Adelaide, SA, Australia
| | - R A Gibson
- SAHMRI Women and Kids, South Australian Health and Medical Research Institute, Adelaide, SA, Australia.,The School of Agriculture, Food and Wine, The University of Adelaide, Adelaide, SA, Australia
| | - M Makrides
- SAHMRI Women and Kids, South Australian Health and Medical Research Institute, Adelaide, SA, Australia.,School of Medicine, The University of Adelaide, Adelaide, SA, Australia
| |
Collapse
|
12
|
Abstract
Reactive oxygen species (ROS) are essential for cellular signaling and physiological function. An imbalance between ROS production and antioxidant protection results in a state of oxidative stress (OS), which is associated with perturbations in reduction/oxidation (redox) regulation, cellular dysfunction, organ failure, and disease. The pathophysiology of OS is closely interlinked with inflammation, mitochondrial dysfunction, and, in the case of surgery, ischemia/reperfusion injury (IRI). Perioperative OS is a complex response that involves patient, surgical, and anesthetic factors. The magnitude of tissue injury inflicted by the surgery affects the degree of OS, and both duration and nature of the anesthetic procedure applied can modify this. Moreover, the interindividual susceptibility to the impact of OS is likely to be highly variable and potentially linked to underlying comorbidities. The pathological link between OS and postoperative complications remains unclear, in part due to the complexities of measuring ROS- and OS-mediated damage. Exogenous antioxidant use and exercise have been shown to modulate OS and may have potential as countermeasures to improve postoperative recovery. A better understanding of the underlying mechanisms of OS, redox signaling, and regulation can provide an opportunity for patient-specific phenotyping and development of targeted interventions to reduce the disruption that surgery can cause to our physiology. Anesthesiologists are in a unique position to deliver countermeasures to OS and improve physiological resilience. To shy away from a process so fundamental to the welfare of these patients would be foolhardy and negligent, thus calling for an improved understanding of this complex facet of human biology.
Collapse
Affiliation(s)
- Jia L Stevens
- From the Division of Surgery and Interventional Science, Royal Free Hospital, University College London, London, United Kingdom
- Royal Free Perioperative Research Group, Department of Anaesthesia, Royal Free Hospital, London, United Kingdom
| | - Martin Feelisch
- Clinical and Experimental Sciences and Integrative Physiology and Critical Illness Group, Faculty of Medicine, Southampton General Hospital and Institute for Life Sciences, University of Southampton, Southampton, United Kingdom
| | - Daniel S Martin
- From the Division of Surgery and Interventional Science, Royal Free Hospital, University College London, London, United Kingdom
- Royal Free Perioperative Research Group, Department of Anaesthesia, Royal Free Hospital, London, United Kingdom
| |
Collapse
|
13
|
Emenaker NJ, Vargas AJ. The Mediterranean Diet, the OGG1 Gene, and Disease Risk: Early Evidence. J Acad Nutr Diet 2018; 118:547-549. [PMID: 29305132 PMCID: PMC5869136 DOI: 10.1016/j.jand.2017.09.026] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2017] [Accepted: 09/27/2017] [Indexed: 12/22/2022]
|
14
|
Abnet CC, Arnold M, Wei WQ. Epidemiology of Esophageal Squamous Cell Carcinoma. Gastroenterology 2018; 154:360-373. [PMID: 28823862 PMCID: PMC5836473 DOI: 10.1053/j.gastro.2017.08.023] [Citation(s) in RCA: 1133] [Impact Index Per Article: 161.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/04/2017] [Revised: 08/08/2017] [Accepted: 08/09/2017] [Indexed: 12/11/2022]
Abstract
Esophageal squamous cell carcinoma (ESCC) accounts for about 90% of the 456,000 incident esophageal cancers each year. Regions of high incidence include Eastern to Central Asia, along the Rift Valley in East Africa, and into South Africa. There are many causes of ESCC, which vary among regions. Early studies in France associated smoking cigarettes and heavy alcohol consumption with high rates of ESCC, but these factors cannot explain the high incidence in other regions. We discuss other risk factors for ESCC, including polycyclic aromatic hydrocarbons from a variety of sources, high-temperature foods, diet, and oral health and the microbiome-all require further research. A growing list of defined genomic regions affects susceptibility, but large genome-wide association studies have been conducted with ethnic Chinese subjects only; more studies are called for in the rest of Asia and Africa. ESCC has been understudied, but growing infrastructure in more high-incidence countries will allow rapid progress in our understanding.
Collapse
Affiliation(s)
- Christian C Abnet
- Metabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland
| | - Melina Arnold
- Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France
| | - Wen-Qiang Wei
- Department of Cancer Epidemiology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China
| |
Collapse
|
15
|
Kuhnle GGC. Nutrition epidemiology of flavan-3-ols: The known unknowns. Mol Aspects Med 2017; 61:2-11. [PMID: 29146101 DOI: 10.1016/j.mam.2017.10.003] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2017] [Revised: 10/19/2017] [Accepted: 10/24/2017] [Indexed: 01/17/2023]
Abstract
Nutritional epidemiology has an important role, as it can provide long-term data from large populations and does not rely on surrogate markers for morbidity/mortality. Meaningful interpretation and applications of outcomes from epidemiological studies depend on the accurate assessment of dietary intake, which is currently mainly based on a combination of self-reporting and food composition data. Flavan-3-ols are a group of bioactives (non-essential dietary components with significant impact on health) that is a possible candidate for the development of dietary recommendations. The breadth of data available on their effect on health also provides the basis for investigating the suitability of the methods currently used in nutritional epidemiology to assess the health effects of bioactives. The outcomes of this assessment demonstrate that the limitations of currently used methods make it virtually impossible to estimate intake accurately from self-reported dietary data. This is due to the limitations of self-reporting, especially from food-frequency questionnaires, and the inability of currently used methods to deal with the high variability of food composition. Indeed, the estimated intake of flavan-3-ols, can only be interpreted as a marker of specific dietary patterns, but not as the actual intake amount. The interpretation of results from such studies are fraught with serious limitations, especially for establishing associations between intake and health and the development of dietary recommendations. Alternative assessment not affected by these limitations, such as biomarkers, are required to overcome these limitations. The development of nutritional biomarkers is therefore crucial to investigate the health effect of bioactives.
Collapse
Affiliation(s)
- Gunter G C Kuhnle
- Department of Food & Nutritional Sciences, Harry Nursten Building, University of Reading, Reading RG6 6UR, United Kingdom.
| |
Collapse
|
16
|
Yetley EA, DeMets DL, Harlan WR. Surrogate disease markers as substitutes for chronic disease outcomes in studies of diet and chronic disease relations. Am J Clin Nutr 2017; 106:1175-1189. [PMID: 29021287 PMCID: PMC5657291 DOI: 10.3945/ajcn.117.164046] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2017] [Accepted: 09/12/2017] [Indexed: 01/09/2023] Open
Abstract
Surrogate biomarkers for clinical outcomes afford scientific and economic efficiencies when investigating nutritional interventions in chronic diseases. However, valid scientific results are dependent on the qualification of these disease markers that are intended to be substitutes for a clinical outcome and to accurately predict benefit or harm. In this article, we examine the challenges of evaluating surrogate markers and describe the framework proposed in a 2010 Institute of Medicine report. The components of this framework are presented in the context of nutritional interventions for chronic diseases. We present case studies of 2 well-accepted surrogate markers [blood pressure within sodium intake and cardiovascular disease (CVD) context and low density lipoprotein-cholesterol concentrations within a saturated fat and CVD context]. We also describe additional cases in which the evidence is insufficient to validate their surrogate status. Guidance is offered for future research that evaluates or uses surrogate markers.
Collapse
Affiliation(s)
| | - David L DeMets
- Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI
| | | |
Collapse
|
17
|
Dimitrov V, Bouttier M, Boukhaled G, Salehi-Tabar R, Avramescu RG, Memari B, Hasaj B, Lukacs GL, Krawczyk CM, White JH. Hormonal vitamin D up-regulates tissue-specific PD-L1 and PD-L2 surface glycoprotein expression in humans but not mice. J Biol Chem 2017; 292:20657-20668. [PMID: 29061851 DOI: 10.1074/jbc.m117.793885] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2017] [Revised: 09/28/2017] [Indexed: 12/14/2022] Open
Abstract
PD-L1 (programmed death ligand 1) and PD-L2 are cell-surface glycoproteins that interact with programmed death 1 (PD-1) on T cells to attenuate inflammation. PD-1 signaling has attracted intense interest for its role in a pathophysiological context: suppression of anti-tumor immunity. Similarly, vitamin D signaling has been increasingly investigated for its non-classical actions in stimulation of innate immunity and suppression of inflammatory responses. Here, we show that hormonal 1,25-dihydroxyvitamin D (1,25D) is a direct transcriptional inducer of the human genes encoding PD-L1 and PD-L2 through the vitamin D receptor, a ligand-regulated transcription factor. 1,25D stimulated transcription of the gene encoding PD-L1 in epithelial and myeloid cells, whereas the gene encoding the more tissue-restricted PD-L2 was regulated only in myeloid cells. We identified and characterized vitamin D response elements (VDREs) located in both genes and showed that 1,25D treatment induces cell-surface expression of PD-L1 in epithelial and myeloid cells. In co-culture experiments with primary human T cells, epithelial cells pretreated with 1,25D suppressed activation of CD4+ and CD8+ cells and inhibited inflammatory cytokine production in a manner that was abrogated by anti-PD-L1 blocking antibody. Consistent with previous observations of species-specific regulation of immunity by vitamin D, the VDREs are present in primate genes, but neither the VDREs nor the regulation by 1,25D is present in mice. These findings reinforce the physiological role of 1,25D in controlling inflammatory immune responses but may represent a double-edged sword, as they suggest that elevated vitamin D signaling in humans could suppress anti-tumor immunity.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Benedeta Hasaj
- Microbiology and Immunology, McGill University, Montreal, Quebec H3G 1Y6, Canada
| | | | - Connie M Krawczyk
- From the Departments of Physiology, .,Microbiology and Immunology, McGill University, Montreal, Quebec H3G 1Y6, Canada
| | - John H White
- From the Departments of Physiology, .,Medicine, and
| |
Collapse
|
18
|
Gaur S, Agnihotri R. Trace Mineral Micronutrients and Chronic Periodontitis-a Review. Biol Trace Elem Res 2017; 176:225-238. [PMID: 27580897 DOI: 10.1007/s12011-016-0832-y] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/02/2016] [Accepted: 08/22/2016] [Indexed: 12/18/2022]
Abstract
Trace mineral micronutrients are imperative for optimum host response. Populations worldwide are prone to their insufficiency owing to lifestyle changes or poor nutritional intake. Balanced levels of trace minerals like iron (Fe), zinc (Zn), selenium (Se) and copper (Cu) are essential to prevent progression of chronic conditions like periodontitis. Their excess as well as deficiency is detrimental to periodontal health. This is specifically true in relation to Fe. Furthermore, some trace elements, e.g. Se, Zn and Cu are integral components of antioxidant enzymes and prevent reactive oxygen species induced destruction of tissues. Their deficiency can worsen periodontitis associated with systemic conditions like diabetes mellitus. With this background, the present review first focusses on the role of four trace minerals, namely, Fe, Zn, Se and Cu in periodontal health followed by an appraisal of the data from case control studies related to their association with chronic periodontitis.
Collapse
Affiliation(s)
- Sumit Gaur
- Department of Pedodontics and Preventive Dentistry, Manipal College of Dental Sciences, Manipal University, Manipal, Karnataka, 576104, India
| | - Rupali Agnihotri
- Department of Periodontology, Manipal College of Dental Sciences, Manipal University, Manipal, Karnataka, 576104, India.
| |
Collapse
|
19
|
Yetley EA, MacFarlane AJ, Greene-Finestone LS, Garza C, Ard JD, Atkinson SA, Bier DM, Carriquiry AL, Harlan WR, Hattis D, King JC, Krewski D, O'Connor DL, Prentice RL, Rodricks JV, Wells GA. Options for basing Dietary Reference Intakes (DRIs) on chronic disease endpoints: report from a joint US-/Canadian-sponsored working group. Am J Clin Nutr 2017; 105:249S-285S. [PMID: 27927637 PMCID: PMC5183726 DOI: 10.3945/ajcn.116.139097] [Citation(s) in RCA: 73] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Dietary Reference Intakes (DRIs) are used in Canada and the United States in planning and assessing diets of apparently healthy individuals and population groups. The approaches used to establish DRIs on the basis of classical nutrient deficiencies and/or toxicities have worked well. However, it has proved to be more challenging to base DRI values on chronic disease endpoints; deviations from the traditional framework were often required, and in some cases, DRI values were not established for intakes that affected chronic disease outcomes despite evidence that supported a relation. The increasing proportions of elderly citizens, the growing prevalence of chronic diseases, and the persistently high prevalence of overweight and obesity, which predispose to chronic disease, highlight the importance of understanding the impact of nutrition on chronic disease prevention and control. A multidisciplinary working group sponsored by the Canadian and US government DRI steering committees met from November 2014 to April 2016 to identify options for addressing key scientific challenges encountered in the use of chronic disease endpoints to establish reference values. The working group focused on 3 key questions: 1) What are the important evidentiary challenges for selecting and using chronic disease endpoints in future DRI reviews, 2) what intake-response models can future DRI committees consider when using chronic disease endpoints, and 3) what are the arguments for and against continuing to include chronic disease endpoints in future DRI reviews? This report outlines the range of options identified by the working group for answering these key questions, as well as the strengths and weaknesses of each option.
Collapse
Affiliation(s)
| | | | | | - Cutberto Garza
- Boston College, Chestnut Hill, MA
- Department of Global Health, George Washington University Milken Institute School of Public Health, Washington, DC
- Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD
| | - Jamy D Ard
- Wake Forest School of Medicine, Wake Forest University, Winston-Salem, NC
| | | | - Dennis M Bier
- Children's Nutrition Research Center, Baylor College of Medicine, Houston, TX
| | | | | | - Dale Hattis
- The George Perkins Marsh Institute, Clark University, Worcester, MA
| | - Janet C King
- Children's Hospital Oakland Research Institute, Oakland, CA
- Department of Nutritional Sciences, University of California, Berkeley, Berkeley, CA
- Department of Nutrition, University of California, Davis, Davis, CA
| | - Daniel Krewski
- McLaughlin Centre for Population Health Risk Assessment, University of Ottawa, Ottawa, Ontario, Canada
| | - Deborah L O'Connor
- Department of Nutritional Sciences, University of Toronto
- The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Ross L Prentice
- Fred Hutchinson Cancer Research Center
- School of Public Health, University of Washington, Seattle, WA
| | | | - George A Wells
- Department of Epidemiology and Community Medicine, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| |
Collapse
|
20
|
Meyskens FL. What to Do With the Participants/Patients in Phase III Clinical Cancer Trials That Have Been Stopped by the FDA. J Natl Cancer Inst 2016; 108:djw252. [DOI: 10.1093/jnci/djw252] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2016] [Accepted: 09/27/2016] [Indexed: 11/13/2022] Open
|
21
|
Thompson PA, Ashbeck EL, Roe DJ, Fales L, Buckmeier J, Wang F, Bhattacharyya A, Hsu CH, Chow HHS, Ahnen DJ, Boland CR, Heigh RI, Fay DE, Hamilton SR, Jacobs ET, Martinez ME, Alberts DS, Lance P. Selenium Supplementation for Prevention of Colorectal Adenomas and Risk of Associated Type 2 Diabetes. J Natl Cancer Inst 2016; 108:djw152. [PMID: 27530657 DOI: 10.1093/jnci/djw152] [Citation(s) in RCA: 73] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2015] [Accepted: 05/17/2016] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Selenium supplementation may help to prevent colorectal cancer; as precursors of colorectal cancer, colorectal adenomas are a surrogate for colorectal cancer. Selenium supplementation may increase risk of type 2 diabetes (T2D). METHODS The Selenium and Celecoxib (Sel/Cel) Trial was a randomized, placebo controlled trial of selenium 200 µg daily as selenized yeast and celecoxib 400 mg once daily, alone or together, for colorectal adenoma prevention. Men and women between age 40 and 80 years were eligible following colonoscopic removal of colorectal adenomas. The primary outcome was adenoma development. Celecoxib was suspended because of cardiovascular toxicity in other trials, but accrual continued to selenium and placebo. A total of 1621 participants were randomly assigned to selenium or placebo, of whom 1374 (84.8%) were available for analysis. All statistical tests were two-sided. RESULTS In the respective placebo and selenium arms of 689 and 685 participants, adenoma detection after medians of 33.6 (range = 0.0-85.1 months) and 33.0 months (range = 0.0-82.6 months) were 42.8% and 44.1% (relative risk [RR] = 1.03, 95% confidence interval [CI] = 0.91 to 1.16, P = .68). In participants with baseline advanced adenomas, adenoma recurrence was reduced by 18% with selenium (RR = 0.82, 95% CI = 0.71 to 0.96, P = .01). In participants receiving selenium, the hazard ratio for new-onset T2D was 1.25 (95% CI = 0.74 to 2.11, P = .41), with a statistically significantly increased risk of selenium-associated T2D among older participants (RR = 2.21; 95% CI = 1.04 to 4.67, P = .03). CONCLUSIONS Overall, selenium did not prevent colorectal adenomas and showed only modest benefit in patients with baseline advanced adenomas. With limited benefit and similar increases in T2D to other trials, selenium is not recommended for preventing colorectal adenomas in selenium-replete individuals.
Collapse
Affiliation(s)
- Patricia A Thompson
- University of Arizona Cancer Center, Tucson, AZ (PAT, ELA, DJR, LF, JB, FW, CHH, HHSC, ETJ, DSA, PL); Department of Pathology, University of Arizona, Tucson, AZ (AB); Denver Department of Veterans Affairs Medical Center and University of Colorado, Denver, CO (DJA); GI Cancer Research Laboratory, Baylor University Medical Center, Dallas, TX (CRB); Division of Gastroenterology & Hepatology, Mayo Clinic, Scottsdale, AZ (RIH); Endoscopy Center of Western New York, Buffalo, NY (DEF); Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX (SRH); University of California, San Diego, Moores Cancer Center, La Jolla, CA (MEM). Current affiliation: Stony Brook University, Stony Brook, New York, NY (PAT)
| | - Erin L Ashbeck
- University of Arizona Cancer Center, Tucson, AZ (PAT, ELA, DJR, LF, JB, FW, CHH, HHSC, ETJ, DSA, PL); Department of Pathology, University of Arizona, Tucson, AZ (AB); Denver Department of Veterans Affairs Medical Center and University of Colorado, Denver, CO (DJA); GI Cancer Research Laboratory, Baylor University Medical Center, Dallas, TX (CRB); Division of Gastroenterology & Hepatology, Mayo Clinic, Scottsdale, AZ (RIH); Endoscopy Center of Western New York, Buffalo, NY (DEF); Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX (SRH); University of California, San Diego, Moores Cancer Center, La Jolla, CA (MEM). Current affiliation: Stony Brook University, Stony Brook, New York, NY (PAT)
| | - Denise J Roe
- University of Arizona Cancer Center, Tucson, AZ (PAT, ELA, DJR, LF, JB, FW, CHH, HHSC, ETJ, DSA, PL); Department of Pathology, University of Arizona, Tucson, AZ (AB); Denver Department of Veterans Affairs Medical Center and University of Colorado, Denver, CO (DJA); GI Cancer Research Laboratory, Baylor University Medical Center, Dallas, TX (CRB); Division of Gastroenterology & Hepatology, Mayo Clinic, Scottsdale, AZ (RIH); Endoscopy Center of Western New York, Buffalo, NY (DEF); Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX (SRH); University of California, San Diego, Moores Cancer Center, La Jolla, CA (MEM). Current affiliation: Stony Brook University, Stony Brook, New York, NY (PAT)
| | - Liane Fales
- University of Arizona Cancer Center, Tucson, AZ (PAT, ELA, DJR, LF, JB, FW, CHH, HHSC, ETJ, DSA, PL); Department of Pathology, University of Arizona, Tucson, AZ (AB); Denver Department of Veterans Affairs Medical Center and University of Colorado, Denver, CO (DJA); GI Cancer Research Laboratory, Baylor University Medical Center, Dallas, TX (CRB); Division of Gastroenterology & Hepatology, Mayo Clinic, Scottsdale, AZ (RIH); Endoscopy Center of Western New York, Buffalo, NY (DEF); Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX (SRH); University of California, San Diego, Moores Cancer Center, La Jolla, CA (MEM). Current affiliation: Stony Brook University, Stony Brook, New York, NY (PAT)
| | - Julie Buckmeier
- University of Arizona Cancer Center, Tucson, AZ (PAT, ELA, DJR, LF, JB, FW, CHH, HHSC, ETJ, DSA, PL); Department of Pathology, University of Arizona, Tucson, AZ (AB); Denver Department of Veterans Affairs Medical Center and University of Colorado, Denver, CO (DJA); GI Cancer Research Laboratory, Baylor University Medical Center, Dallas, TX (CRB); Division of Gastroenterology & Hepatology, Mayo Clinic, Scottsdale, AZ (RIH); Endoscopy Center of Western New York, Buffalo, NY (DEF); Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX (SRH); University of California, San Diego, Moores Cancer Center, La Jolla, CA (MEM). Current affiliation: Stony Brook University, Stony Brook, New York, NY (PAT)
| | - Fang Wang
- University of Arizona Cancer Center, Tucson, AZ (PAT, ELA, DJR, LF, JB, FW, CHH, HHSC, ETJ, DSA, PL); Department of Pathology, University of Arizona, Tucson, AZ (AB); Denver Department of Veterans Affairs Medical Center and University of Colorado, Denver, CO (DJA); GI Cancer Research Laboratory, Baylor University Medical Center, Dallas, TX (CRB); Division of Gastroenterology & Hepatology, Mayo Clinic, Scottsdale, AZ (RIH); Endoscopy Center of Western New York, Buffalo, NY (DEF); Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX (SRH); University of California, San Diego, Moores Cancer Center, La Jolla, CA (MEM). Current affiliation: Stony Brook University, Stony Brook, New York, NY (PAT)
| | - Achyut Bhattacharyya
- University of Arizona Cancer Center, Tucson, AZ (PAT, ELA, DJR, LF, JB, FW, CHH, HHSC, ETJ, DSA, PL); Department of Pathology, University of Arizona, Tucson, AZ (AB); Denver Department of Veterans Affairs Medical Center and University of Colorado, Denver, CO (DJA); GI Cancer Research Laboratory, Baylor University Medical Center, Dallas, TX (CRB); Division of Gastroenterology & Hepatology, Mayo Clinic, Scottsdale, AZ (RIH); Endoscopy Center of Western New York, Buffalo, NY (DEF); Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX (SRH); University of California, San Diego, Moores Cancer Center, La Jolla, CA (MEM). Current affiliation: Stony Brook University, Stony Brook, New York, NY (PAT)
| | - Chiu-Hsieh Hsu
- University of Arizona Cancer Center, Tucson, AZ (PAT, ELA, DJR, LF, JB, FW, CHH, HHSC, ETJ, DSA, PL); Department of Pathology, University of Arizona, Tucson, AZ (AB); Denver Department of Veterans Affairs Medical Center and University of Colorado, Denver, CO (DJA); GI Cancer Research Laboratory, Baylor University Medical Center, Dallas, TX (CRB); Division of Gastroenterology & Hepatology, Mayo Clinic, Scottsdale, AZ (RIH); Endoscopy Center of Western New York, Buffalo, NY (DEF); Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX (SRH); University of California, San Diego, Moores Cancer Center, La Jolla, CA (MEM). Current affiliation: Stony Brook University, Stony Brook, New York, NY (PAT)
| | - H H Sherry Chow
- University of Arizona Cancer Center, Tucson, AZ (PAT, ELA, DJR, LF, JB, FW, CHH, HHSC, ETJ, DSA, PL); Department of Pathology, University of Arizona, Tucson, AZ (AB); Denver Department of Veterans Affairs Medical Center and University of Colorado, Denver, CO (DJA); GI Cancer Research Laboratory, Baylor University Medical Center, Dallas, TX (CRB); Division of Gastroenterology & Hepatology, Mayo Clinic, Scottsdale, AZ (RIH); Endoscopy Center of Western New York, Buffalo, NY (DEF); Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX (SRH); University of California, San Diego, Moores Cancer Center, La Jolla, CA (MEM). Current affiliation: Stony Brook University, Stony Brook, New York, NY (PAT)
| | - Dennis J Ahnen
- University of Arizona Cancer Center, Tucson, AZ (PAT, ELA, DJR, LF, JB, FW, CHH, HHSC, ETJ, DSA, PL); Department of Pathology, University of Arizona, Tucson, AZ (AB); Denver Department of Veterans Affairs Medical Center and University of Colorado, Denver, CO (DJA); GI Cancer Research Laboratory, Baylor University Medical Center, Dallas, TX (CRB); Division of Gastroenterology & Hepatology, Mayo Clinic, Scottsdale, AZ (RIH); Endoscopy Center of Western New York, Buffalo, NY (DEF); Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX (SRH); University of California, San Diego, Moores Cancer Center, La Jolla, CA (MEM). Current affiliation: Stony Brook University, Stony Brook, New York, NY (PAT)
| | - C Richard Boland
- University of Arizona Cancer Center, Tucson, AZ (PAT, ELA, DJR, LF, JB, FW, CHH, HHSC, ETJ, DSA, PL); Department of Pathology, University of Arizona, Tucson, AZ (AB); Denver Department of Veterans Affairs Medical Center and University of Colorado, Denver, CO (DJA); GI Cancer Research Laboratory, Baylor University Medical Center, Dallas, TX (CRB); Division of Gastroenterology & Hepatology, Mayo Clinic, Scottsdale, AZ (RIH); Endoscopy Center of Western New York, Buffalo, NY (DEF); Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX (SRH); University of California, San Diego, Moores Cancer Center, La Jolla, CA (MEM). Current affiliation: Stony Brook University, Stony Brook, New York, NY (PAT)
| | - Russell I Heigh
- University of Arizona Cancer Center, Tucson, AZ (PAT, ELA, DJR, LF, JB, FW, CHH, HHSC, ETJ, DSA, PL); Department of Pathology, University of Arizona, Tucson, AZ (AB); Denver Department of Veterans Affairs Medical Center and University of Colorado, Denver, CO (DJA); GI Cancer Research Laboratory, Baylor University Medical Center, Dallas, TX (CRB); Division of Gastroenterology & Hepatology, Mayo Clinic, Scottsdale, AZ (RIH); Endoscopy Center of Western New York, Buffalo, NY (DEF); Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX (SRH); University of California, San Diego, Moores Cancer Center, La Jolla, CA (MEM). Current affiliation: Stony Brook University, Stony Brook, New York, NY (PAT)
| | - David E Fay
- University of Arizona Cancer Center, Tucson, AZ (PAT, ELA, DJR, LF, JB, FW, CHH, HHSC, ETJ, DSA, PL); Department of Pathology, University of Arizona, Tucson, AZ (AB); Denver Department of Veterans Affairs Medical Center and University of Colorado, Denver, CO (DJA); GI Cancer Research Laboratory, Baylor University Medical Center, Dallas, TX (CRB); Division of Gastroenterology & Hepatology, Mayo Clinic, Scottsdale, AZ (RIH); Endoscopy Center of Western New York, Buffalo, NY (DEF); Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX (SRH); University of California, San Diego, Moores Cancer Center, La Jolla, CA (MEM). Current affiliation: Stony Brook University, Stony Brook, New York, NY (PAT)
| | - Stanley R Hamilton
- University of Arizona Cancer Center, Tucson, AZ (PAT, ELA, DJR, LF, JB, FW, CHH, HHSC, ETJ, DSA, PL); Department of Pathology, University of Arizona, Tucson, AZ (AB); Denver Department of Veterans Affairs Medical Center and University of Colorado, Denver, CO (DJA); GI Cancer Research Laboratory, Baylor University Medical Center, Dallas, TX (CRB); Division of Gastroenterology & Hepatology, Mayo Clinic, Scottsdale, AZ (RIH); Endoscopy Center of Western New York, Buffalo, NY (DEF); Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX (SRH); University of California, San Diego, Moores Cancer Center, La Jolla, CA (MEM). Current affiliation: Stony Brook University, Stony Brook, New York, NY (PAT)
| | - Elizabeth T Jacobs
- University of Arizona Cancer Center, Tucson, AZ (PAT, ELA, DJR, LF, JB, FW, CHH, HHSC, ETJ, DSA, PL); Department of Pathology, University of Arizona, Tucson, AZ (AB); Denver Department of Veterans Affairs Medical Center and University of Colorado, Denver, CO (DJA); GI Cancer Research Laboratory, Baylor University Medical Center, Dallas, TX (CRB); Division of Gastroenterology & Hepatology, Mayo Clinic, Scottsdale, AZ (RIH); Endoscopy Center of Western New York, Buffalo, NY (DEF); Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX (SRH); University of California, San Diego, Moores Cancer Center, La Jolla, CA (MEM). Current affiliation: Stony Brook University, Stony Brook, New York, NY (PAT)
| | - Maria Elena Martinez
- University of Arizona Cancer Center, Tucson, AZ (PAT, ELA, DJR, LF, JB, FW, CHH, HHSC, ETJ, DSA, PL); Department of Pathology, University of Arizona, Tucson, AZ (AB); Denver Department of Veterans Affairs Medical Center and University of Colorado, Denver, CO (DJA); GI Cancer Research Laboratory, Baylor University Medical Center, Dallas, TX (CRB); Division of Gastroenterology & Hepatology, Mayo Clinic, Scottsdale, AZ (RIH); Endoscopy Center of Western New York, Buffalo, NY (DEF); Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX (SRH); University of California, San Diego, Moores Cancer Center, La Jolla, CA (MEM). Current affiliation: Stony Brook University, Stony Brook, New York, NY (PAT)
| | - David S Alberts
- University of Arizona Cancer Center, Tucson, AZ (PAT, ELA, DJR, LF, JB, FW, CHH, HHSC, ETJ, DSA, PL); Department of Pathology, University of Arizona, Tucson, AZ (AB); Denver Department of Veterans Affairs Medical Center and University of Colorado, Denver, CO (DJA); GI Cancer Research Laboratory, Baylor University Medical Center, Dallas, TX (CRB); Division of Gastroenterology & Hepatology, Mayo Clinic, Scottsdale, AZ (RIH); Endoscopy Center of Western New York, Buffalo, NY (DEF); Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX (SRH); University of California, San Diego, Moores Cancer Center, La Jolla, CA (MEM). Current affiliation: Stony Brook University, Stony Brook, New York, NY (PAT)
| | - Peter Lance
- University of Arizona Cancer Center, Tucson, AZ (PAT, ELA, DJR, LF, JB, FW, CHH, HHSC, ETJ, DSA, PL); Department of Pathology, University of Arizona, Tucson, AZ (AB); Denver Department of Veterans Affairs Medical Center and University of Colorado, Denver, CO (DJA); GI Cancer Research Laboratory, Baylor University Medical Center, Dallas, TX (CRB); Division of Gastroenterology & Hepatology, Mayo Clinic, Scottsdale, AZ (RIH); Endoscopy Center of Western New York, Buffalo, NY (DEF); Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX (SRH); University of California, San Diego, Moores Cancer Center, La Jolla, CA (MEM). Current affiliation: Stony Brook University, Stony Brook, New York, NY (PAT)
| |
Collapse
|
22
|
Saba G, Nieto I, Bation R, Allaïli N, Bennabi D, Moliere F, Richieri R, Holtzmann J, Bubrovszky M, Camus V, Charpeaud T, Courtet P, Courvoisier P, Haesebaert F, Doumy O, El-Hage W, Garnier M, d'Amato T, Bougerol T, Lançon C, Haffen E, Llorca PM, Vaiva G, Bellivier F, Leboyer M, Aouizerate B. [Other therapeutic strategies]. Presse Med 2016; 45:350-9. [PMID: 26995510 DOI: 10.1016/j.lpm.2016.02.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Non-selective and irreversible MAOI have become as third or fourth-line strategy for the management of treatment-resistant depression. Non-selective and irreversible MAOI requires careful monitoring of drug interactions and dietary restrictions. Nutritional supplements such as omega-3 have been found to produce beneficial effects in the management of treatment-resistant depression when administered in combination with the ongoing antidepressant treatment. The glutamate antagonist ketamine has been found to produce beneficial effects in the management of treatment-resistant depression while administered alone. Dopamine and/or norepinephrine agonists, such as methylphenidate, modafinil or pramipexole, have been found to produce beneficial effects in the management of treatment-resistant depression when administered in combination with the ongoing antidepressant treatment.
Collapse
Affiliation(s)
- Ghassen Saba
- Henri-Mondor, hôpital Chenevier, pôle de psychiatrie des hôpitaux universitaires, centre expert dépression résistante FondaMental, 94000 Créteil, France.
| | - Isabel Nieto
- Hôpital Fernand-Widal, service de psychiatrie adulte, centre expert dépression résistante FondaMental, 75010 Paris, France
| | - Rémy Bation
- Centre hospitalier Le Vinatier, service universitaire de psychiatrie adulte, centre expert dépression résistante FondaMental, BP 300 39, 69678 Bron cedex, France
| | - Najib Allaïli
- Hôpital Fernand-Widal, service de psychiatrie adulte, centre expert dépression résistante FondaMental, 75010 Paris, France
| | - Djamila Bennabi
- CHU de Besançon, service de psychiatrie de l'adulte, centre expert dépression résistante FondaMental, 25030 Besançon cedex, France
| | - Fanny Moliere
- CHRU Lapeyronie, département des urgences et post-urgences psychiatrique, centre expert dépression résistante FondaMental, 34295 Montpellier cedex 5, France
| | - Raphaëlle Richieri
- CHU La Conception, pôle psychiatrie centre, centre expert dépression résistante FondaMental, 13005 Marseille, France
| | - Jérôme Holtzmann
- CHU de Grenoble, hôpital Nord, service de psychiatrie de l'adulte, centre expert dépression résistante FondaMental, CS 10217, 38043 Grenoble cedex 9, France
| | - Maxime Bubrovszky
- CHRU de Lille, hôpital Fontan 1, service de psychiatrie adulte, centre expert dépression résistante FondaMental, 59037 Lille cedex, France
| | - Vincent Camus
- CHU de Tours, clinique psychiatrique universitaire, centre expert dépression résistante FondaMental, 37044 Tours cedex 9, France
| | - Thomas Charpeaud
- CHU de Clermont-Ferrand, service de psychiatrie de l'adulte B, centre expert dépression résistante FondaMental, 63003 Clermont-Ferrand, France
| | - Philippe Courtet
- CHRU Lapeyronie, département des urgences et post-urgences psychiatrique, centre expert dépression résistante FondaMental, 34295 Montpellier cedex 5, France
| | - Pierre Courvoisier
- CHU de Grenoble, hôpital Nord, service de psychiatrie de l'adulte, centre expert dépression résistante FondaMental, CS 10217, 38043 Grenoble cedex 9, France
| | - Frédéric Haesebaert
- Centre hospitalier Le Vinatier, service universitaire de psychiatrie adulte, centre expert dépression résistante FondaMental, BP 300 39, 69678 Bron cedex, France
| | - Olivier Doumy
- CH Charles-Perrens, pôle de psychiatrie générale et universitaire, centre expert dépression résistante FondaMental, 33076 Bordeaux cedex, France
| | - Wissam El-Hage
- CHU de Tours, clinique psychiatrique universitaire, centre expert dépression résistante FondaMental, 37044 Tours cedex 9, France
| | - Marion Garnier
- CHU de Clermont-Ferrand, service de psychiatrie de l'adulte B, centre expert dépression résistante FondaMental, 63003 Clermont-Ferrand, France
| | - Thierry d'Amato
- Centre hospitalier Le Vinatier, service universitaire de psychiatrie adulte, centre expert dépression résistante FondaMental, BP 300 39, 69678 Bron cedex, France
| | - Thierry Bougerol
- CHU de Grenoble, hôpital Nord, service de psychiatrie de l'adulte, centre expert dépression résistante FondaMental, CS 10217, 38043 Grenoble cedex 9, France
| | - Christophe Lançon
- CHU La Conception, pôle psychiatrie centre, centre expert dépression résistante FondaMental, 13005 Marseille, France
| | - Emmanuel Haffen
- CHU de Besançon, service de psychiatrie de l'adulte, centre expert dépression résistante FondaMental, 25030 Besançon cedex, France
| | - Pierre-Michel Llorca
- CHU de Clermont-Ferrand, service de psychiatrie de l'adulte B, centre expert dépression résistante FondaMental, 63003 Clermont-Ferrand, France
| | - Guillaume Vaiva
- CHRU de Lille, hôpital Fontan 1, service de psychiatrie adulte, centre expert dépression résistante FondaMental, 59037 Lille cedex, France
| | - Frank Bellivier
- Hôpital Fernand-Widal, service de psychiatrie adulte, centre expert dépression résistante FondaMental, 75010 Paris, France
| | - Marion Leboyer
- Henri-Mondor, hôpital Chenevier, pôle de psychiatrie des hôpitaux universitaires, centre expert dépression résistante FondaMental, 94000 Créteil, France
| | - Bruno Aouizerate
- CH Charles-Perrens, pôle de psychiatrie générale et universitaire, centre expert dépression résistante FondaMental, 33076 Bordeaux cedex, France
| |
Collapse
|
23
|
Abstract
Despite the potentially important roles of diet and nutrition in cancer prevention, the evidence to support these roles is widely perceived by the public and health professionals as being inconsistent. In this Review, we present the issues and challenges in conducting and interpreting diet-cancer research, including those relating to the design of epidemiological studies, dietary data collection methods, and factors that affect the outcome of intervention trials. Approaches to improve effect estimates, such as the use of biomarkers to improve the accuracy of characterizing dietary exposures, are also discussed. Nutritional and dietary patterns are complex; therefore, the use of a reductionist approach to investigations, by focusing on specific nutrients, can produce misleading information. The effects of tumour heterogeneity and the failure to appreciate the nonlinear, U-shaped relationship between micronutrients and cancer in both observational studies and clinical trials are discussed. New technologies and investigational approaches are enabling the exploration of complex interactions between genetic, epigenetic, metabolic, and gut-microbial processes that will inform our knowledge of the diet-cancer relationship. Communicating the status of the evolving science in the context of the overall scientific evidence base, and evidence-based dietary recommendations for cancer prevention, should be emphasized in guidance for the public and for individual patients.
Collapse
|
24
|
Scott-Boyer MP, Lacroix S, Scotti M, Morine MJ, Kaput J, Priami C. A network analysis of cofactor-protein interactions for analyzing associations between human nutrition and diseases. Sci Rep 2016; 6:19633. [PMID: 26777674 PMCID: PMC4726080 DOI: 10.1038/srep19633] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2015] [Accepted: 12/14/2015] [Indexed: 11/09/2022] Open
Abstract
The involvement of vitamins and other micronutrients in intermediary metabolism was elucidated in the mid 1900's at the level of individual biochemical reactions. Biochemical pathways remain the foundational knowledgebase for understanding how micronutrient adequacy modulates health in all life stages. Current daily recommended intakes were usually established on the basis of the association of a single nutrient to a single, most sensitive adverse effect and thus neglect interdependent and pleiotropic effects of micronutrients on biological systems. Hence, the understanding of the impact of overt or sub-clinical nutrient deficiencies on biological processes remains incomplete. Developing a more complete view of the role of micronutrients and their metabolic products in protein-mediated reactions is of importance. We thus integrated and represented cofactor-protein interaction data from multiple and diverse sources into a multi-layer network representation that links cofactors, cofactor-interacting proteins, biological processes, and diseases. Network representation of this information is a key feature of the present analysis and enables the integration of data from individual biochemical reactions and protein-protein interactions into a systems view, which may guide strategies for targeted nutritional interventions aimed at improving health and preventing diseases.
Collapse
Affiliation(s)
- Marie Pier Scott-Boyer
- The Microsoft Research - University of Trento Centre for Computational and Systems Biology (COSBI), Rovereto (TN), Italy
| | - Sébastien Lacroix
- The Microsoft Research - University of Trento Centre for Computational and Systems Biology (COSBI), Rovereto (TN), Italy
| | - Marco Scotti
- The Microsoft Research - University of Trento Centre for Computational and Systems Biology (COSBI), Rovereto (TN), Italy.,GEOMAR Helmholtz Centre for Ocean Research Kiel, Kiel, Germany
| | - Melissa J Morine
- The Microsoft Research - University of Trento Centre for Computational and Systems Biology (COSBI), Rovereto (TN), Italy
| | - Jim Kaput
- Nestlé Institute of Health Sciences, Lausanne, Switzerland
| | - Corrado Priami
- The Microsoft Research - University of Trento Centre for Computational and Systems Biology (COSBI), Rovereto (TN), Italy.,Department of Mathematics, University of Trento, Italy
| |
Collapse
|
25
|
Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Dizon D, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Raza M, Rodriguez MA, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA. Survivorship: nutrition and weight management, Version 2.2014. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2015; 12:1396-406. [PMID: 25313179 DOI: 10.6004/jnccn.2014.0137] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Healthy lifestyle habits have been associated with improved health outcomes and quality of life and, for some cancers, a reduced risk of recurrence and death. The NCCN Guidelines for Survivorship therefore recommend that cancer survivors be encouraged to achieve and maintain a healthy lifestyle, including attention to weight management, physical activity, and dietary habits. This section of the NCCN Guidelines focuses on recommendations regarding nutrition, weight management, and supplement use in survivors. Weight management recommendations are based on the survivor's body mass index and include discussions of nutritional, weight management, and physical activity principles, with referral to community resources, dietitians, and/or weight management programs as needed.
Collapse
|
26
|
Abnet CC, Corley DA, Freedman ND, Kamangar F. Diet and upper gastrointestinal malignancies. Gastroenterology 2015; 148:1234-1243.e4. [PMID: 25680671 PMCID: PMC4414068 DOI: 10.1053/j.gastro.2015.02.007] [Citation(s) in RCA: 68] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/06/2014] [Revised: 02/02/2015] [Accepted: 02/05/2015] [Indexed: 02/06/2023]
Abstract
Diet is believed to modulate cancer risk and this relationship has been widely studied in the gastrointestinal tract. Observational epidemiologic studies have provided most of the evidence about the effects of diet on cancer risk because clinical trials to determine nutritional exposures are often impossible, impractical, or unaffordable. Although a few foods or nutrients are thought to protect against specific types of cancer, it seems clear that the strength and even direction of dietary associations (increasing or decreasing risk) is organ-site- and even histology-specific, along the gastrointestinal tract. Although some hypotheses are supported by a substantial body of observational data (drinking hot maté [an infusion of the herb Ilex Paraguarensis] contributes to esophageal cancer), there are not much data to support others. We discuss some highly touted hypotheses and draw interim conclusions about what is known and what could be done to improve the level of evidence. The complex nature of diet and its associations can be productively investigated with disease-specific studies. However, public health recommendations for normal-risk individuals regarding diet and gastrointestinal cancer should probably emphasize the importance of eating for overall health rather than eating specific foods to reduce risk for specific cancers.
Collapse
Affiliation(s)
- Christian C. Abnet
- Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD,Address for Correspondence: Christian Abnet, PhD, MPH, Senior Investigator, Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center Dr Rm 6e344 MSC 9768, Bethesda MD 20892, Office: (240) 276-7213, Mobile: (240) 505-6299,
| | - Douglas A. Corley
- Division of Research, Kaiser Permanente of Northern California, Oakland, CA
| | - Neal D. Freedman
- Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD
| | - Farin Kamangar
- Department of Public Health Analysis, School of Community Health and Policy, Morgan State University, Baltimore, MD,Digestive Oncology Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
27
|
Vinceti M, Dennert G, Crespi CM, Zwahlen M, Brinkman M, Zeegers MPA, Horneber M, D'Amico R, Del Giovane C. Selenium for preventing cancer. Cochrane Database Syst Rev 2014; 2014:CD005195. [PMID: 24683040 PMCID: PMC4441528 DOI: 10.1002/14651858.cd005195.pub3] [Citation(s) in RCA: 73] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
BACKGROUND This review is an update of the first Cochrane publication on selenium for preventing cancer (Dennert 2011).Selenium is a metalloid with both nutritional and toxicological properties. Higher selenium exposure and selenium supplements have been suggested to protect against several types of cancers. OBJECTIVES Two research questions were addressed in this review: What is the evidence for:1. an aetiological relation between selenium exposure and cancer risk in humans? and2. the efficacy of selenium supplementation for cancer prevention in humans? SEARCH METHODS We conducted electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL, 2013, Issue 1), MEDLINE (Ovid, 1966 to February 2013 week 1), EMBASE (1980 to 2013 week 6), CancerLit (February 2004) and CCMed (February 2011). As MEDLINE now includes the journals indexed in CancerLit, no further searches were conducted in this database after 2004. SELECTION CRITERIA We included prospective observational studies (cohort studies including sub-cohort controlled studies and nested case-control studies) and randomised controlled trials (RCTs) with healthy adult participants (18 years of age and older). DATA COLLECTION AND ANALYSIS For observational studies, we conducted random effects meta-analyses when five or more studies were retrieved for a specific outcome. For RCTs, we performed random effects meta-analyses when two or more studies were available. The risk of bias in observational studies was assessed using forms adapted from the Newcastle-Ottawa Quality Assessment Scale for cohort and case-control studies; the criteria specified in the Cochrane Handbook for Systematic Reviews of Interventions were used to evaluate the risk of bias in RCTs. MAIN RESULTS We included 55 prospective observational studies (including more than 1,100,000 participants) and eight RCTs (with a total of 44,743 participants). For the observational studies, we found lower cancer incidence (summary odds ratio (OR) 0.69, 95% confidence interval (CI) 0.53 to 0.91, N = 8) and cancer mortality (OR 0.60, 95% CI 0.39 to 0.93, N = 6) associated with higher selenium exposure. Gender-specific subgroup analysis provided no clear evidence of different effects in men and women (P value 0.47), although cancer incidence was lower in men (OR 0.66, 95% CI 0.42 to 1.05, N = 6) than in women (OR 0.90, 95% CI 0.45 to 1.77, N = 2). The most pronounced decreases in risk of site-specific cancers were seen for stomach, bladder and prostate cancers. However, these findings have limitations due to study design, quality and heterogeneity that complicate interpretation of the summary statistics. Some studies suggested that genetic factors may modify the relation between selenium and cancer risk-a hypothesis that deserves further investigation.In RCTs, we found no clear evidence that selenium supplementation reduced the risk of any cancer (risk ratio (RR) 0.90, 95% CI 0.70 to 1.17, two studies, N = 4765) or cancer-related mortality (RR 0.81, 95% CI 0.49 to 1.32, two studies, N = 18,698), and this finding was confirmed when the analysis was restricted to studies with low risk of bias. The effect on prostate cancer was imprecise (RR 0.90, 95% CI 0.71 to 1.14, four studies, N = 19,110), and when the analysis was limited to trials with low risk of bias, the interventions showed no effect (RR 1.02, 95% CI 0.90 to 1.14, three studies, N = 18,183). The risk of non-melanoma skin cancer was increased (RR 1.44, 95% CI 0.95 to 1.17, three studies, N = 1900). Results of two trials-the Nutritional Prevention of Cancer Trial (NPCT) and the Selenium and Vitamin E Cancer Trial (SELECT)-also raised concerns about possible increased risk of type 2 diabetes, alopecia and dermatitis due to selenium supplements. An early hypothesis generated by NPCT that individuals with the lowest blood selenium levels at baseline could reduce their risk of cancer, particularly of prostate cancer, by increasing selenium intake has not been confirmed by subsequent trials. As the RCT participants were overwhelmingly male (94%), gender differences could not be systematically assessed. AUTHORS' CONCLUSIONS Although an inverse association between selenium exposure and the risk of some types of cancer was found in some observational studies, this cannot be taken as evidence of a causal relation, and these results should be interpreted with caution. These studies have many limitations, including issues with assessment of exposure to selenium and to its various chemical forms, heterogeneity, confounding and other biases. Conflicting results including inverse, null and direct associations have been reported for some cancer types.RCTs assessing the effects of selenium supplementation on cancer risk have yielded inconsistent results, although the most recent studies, characterised by a low risk of bias, found no beneficial effect on cancer risk, more specifically on risk of prostate cancer, as well as little evidence of any influence of baseline selenium status. Rather, some trials suggest harmful effects of selenium exposure. To date, no convincing evidence suggests that selenium supplements can prevent cancer in humans.
Collapse
Affiliation(s)
- Marco Vinceti
- University of Modena and Reggio EmiliaDepartment of Diagnostic, Clinical and Public Health MedicineVia Campi 287ModenaItaly41125
| | - Gabriele Dennert
- University of Applied Sciences DortmundSocial Medicine and Public Health with Focus on Gender and Diversity, Department of Applied Social SciencesEmil‐Figge‐Str. 44DortmundGermanyD‐44227
| | - Catherine M Crespi
- University of California Los AngelesBiostatisticsFielding School of Public Health650 Charles Young Drive South, A2‐125 CHS, Box 95690090095‐6900USALos Angeles
| | - Marcel Zwahlen
- University of BernInstitute of Social and Preventive MedicineFinkelhubelweg11BernSwitzerland3012
| | - Maree Brinkman
- Cancer Council VictoriaCancer Epidemiology Centre615 St Kilda RdMelbourneAustralia3004
| | | | - Markus Horneber
- Paracelsus Medical University, Klinikum NurembergDepartment of Internal Medicine, Division of Oncology and HematologyProf.‐Ernst‐Nathan‐Str. 1NurembergGermanyD‐90419
| | - Roberto D'Amico
- University of Modena and Reggio EmiliaItalian Cochrane Centre, Department of Diagnostic, Clinical and Public Health MedicineVia del Pozzo 71ModenaItaly41124
| | - Cinzia Del Giovane
- University of Modena and Reggio EmiliaItalian Cochrane Centre, Department of Diagnostic, Clinical and Public Health MedicineVia del Pozzo 71ModenaItaly41124
| |
Collapse
|
28
|
Csizmadi I, Kelemen LE, Speidel T, Yuan Y, Dale LC, Friedenreich CM, Robson PJ. Are Physical Activity Levels Linked to Nutrient Adequacy? Implications for Cancer Risk. Nutr Cancer 2014; 66:214-24. [DOI: 10.1080/01635581.2014.868913] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
29
|
Kristal AR, Darke AK, Morris JS, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL, Goodman GE, Minasian LM, Parnes HL, Lippman SM, Klein EA. Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J Natl Cancer Inst 2014; 106:djt456. [PMID: 24563519 DOI: 10.1093/jnci/djt456] [Citation(s) in RCA: 180] [Impact Index Per Article: 16.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND The Selenium and Vitamin E Cancer Prevention Trial found no effect of selenium supplementation on prostate cancer (PCa) risk but a 17% increased risk from vitamin E supplementation. This case-cohort study investigates effects of selenium and vitamin E supplementation conditional upon baseline selenium status. METHODS There were 1739 total and 489 high-grade (Gleason 7-10) PCa cases and 3117 men in the randomly selected cohort. Proportional hazards models estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for effects of supplementation within quintiles of baseline toenail selenium. Cox proportional hazards models were used to estimate hazard ratios, and all statistical tests are two-sided. RESULTS Toenail selenium, in the absence of supplementation, was not associated with PCa risk. Selenium supplementation (combined selenium only and selenium + vitamin E arms) had no effect among men with low selenium status (<60th percentile of toenail selenium) but increased the risk of high-grade PCa among men with higher selenium status by 91% (P = .007). Vitamin E supplementation (alone) had no effect among men with high selenium status (≥40th percentile of toenail selenium) but increased the risks of total, low-grade, and high-grade PCa among men with lower selenium status (63%, P = .02; 46%, P = .09; 111%, P = .008, respectively). CONCLUSIONS Selenium supplementation did not benefit men with low selenium status but increased the risk of high-grade PCa among men with high selenium status. Vitamin E increased the risk of PCa among men with low selenium status. Men should avoid selenium or vitamin E supplementation at doses that exceed recommended dietary intakes.
Collapse
Affiliation(s)
- Alan R Kristal
- Affiliations of authors: Cancer Prevention Program (ARK) and SWOG Statistical Center (AKD, CMT, PJG), Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Epidemiology (ARK, GEG) and Department of Environmental Health (GEG), University of Washington, Seattle, WA; University of Missouri, Research Reactor Center, Columbia, MO (JSM); Harry S. Truman Memorial Veterans Hospital, Columbia, MO (JSM); Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX (IMT); Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA (FLM); Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD (LMM, HLP); Moores Cancer Center, University of California San Diego, San Diego, CA (SML); Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH (EAK)
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Mayne ST. Oxidative stress, dietary antioxidant supplements, and health: is the glass half full or half empty? Cancer Epidemiol Biomarkers Prev 2013; 22:2145-7. [PMID: 24130222 DOI: 10.1158/1055-9965.epi-13-1026] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Affiliation(s)
- Susan T Mayne
- Author's Affiliation: Yale Schools of Public Health and Medicine and Yale Cancer Center, New Haven, Connecticut
| |
Collapse
|
31
|
Affiliation(s)
- John H White
- Departments of Physiology and Medicine, McGill University, 3655 Drummond Street, Room 1112, Montreal, QC H3G 1Y6, Canada.
| |
Collapse
|
32
|
Goyal A, Terry MB, Siegel AB. Serum antioxidant nutrients, vitamin A, and mortality in U.S. Adults. Cancer Epidemiol Biomarkers Prev 2013; 22:2202-11. [PMID: 23897583 DOI: 10.1158/1055-9965.epi-13-0381] [Citation(s) in RCA: 62] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Observational studies have suggested that antioxidant nutrients may reduce cancer and overall mortality risks. However, most randomized trials have failed to show survival benefits. Examining nonlinear associations between antioxidant levels and health outcomes may help to explain these discrepant findings. METHODS We evaluated all-cause, cancer, and cardiovascular mortality risks associated with quintiles (Q1-Q5) of serum antioxidant (vitamins C and E, β-carotene, and selenium) and vitamin A levels, in 16,008 adult participants of The Third National Health and Nutrition Examination Survey (NHANES III; 1988-1994). RESULTS Over a median follow-up period of 14.2 years, there were 4,225 deaths, including 891 from cancer and 1,891 from cardiovascular disease. We observed a dose-response decrease in cancer and overall mortality risks with higher vitamin C levels. In contrast, for vitamin A, risk of cancer death decreased from Q1-Q2, with no further decline in risk at higher levels. For vitamin E, having levels in Q4 was associated with the lowest cancer mortality risk. Both vitamin A and E had U-shaped associations with all-cause mortality. Cancer mortality risks decreased from Q1-Q2 for β-carotene and from Q1-Q4 for selenium. However, for β-carotene and selenium, overall mortality risks decreased from Q1-Q2 but then did not change significantly with higher levels. CONCLUSIONS Antioxidant supplement use should be studied in the context of overall mortality and other competing mortality risks. IMPACT These data suggest the need for novel intervention studies where doses of these agents are individualized based on their serum levels, and possibly, markers of oxidative stress and systemic inflammatory response.
Collapse
Affiliation(s)
- Abhishek Goyal
- Authors' Affiliations: Department of Epidemiology, Columbia University Mailman School of Public Health and Departments of Medicine and Surgery, Columbia University College of Physicians and Surgeons, New York, New York
| | | | | |
Collapse
|
33
|
Abstract
Misconceptions about vitamin D continue to grow despite publications in the past few years that have attempted to clarify risk. We present our perspective, and offer several conclusions. Calcium and vitamin D supplementation can reduce fracture risk by ∼10%. On the other hand, little evidence exists to support a threshold measure for vitamin D status (serum levels of 25-hydroxyvitamin D) above which fractures are reduced. The association of serum concentrations of 25-hydroxyvitamin D with other chronic diseases is confounded by multiple factors and conflicting outcomes that cannot be used to support a causal association. High doses of vitamin D supplements might not be completely harmless and should be avoided until additional data becomes available. Similarly, scant rationale exists for aggressive vitamin D supplementation for pregnant or lactating women. Dispelling misconceptions about vitamin D will ultimately benefit health-care providers and patients alike.
Collapse
Affiliation(s)
- Clifford J Rosen
- Maine Medical Center Research Institute, 81 Research Drive, Scarborough, ME 04074, USA.
| | | |
Collapse
|
34
|
Morris JS, Crane SB. Selenium toxicity from a misformulated dietary supplement, adverse health effects, and the temporal response in the nail biologic monitor. Nutrients 2013; 5:1024-57. [PMID: 23538937 PMCID: PMC3705333 DOI: 10.3390/nu5041024] [Citation(s) in RCA: 75] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2012] [Revised: 03/12/2013] [Accepted: 03/13/2013] [Indexed: 01/08/2023] Open
Abstract
Use of dietary supplements in the U.S. has increased steadily over the last 25 years. While misformulation is uncommon, the consequences can be serious. A March 2008 voluntary market recall removed supplement products responsible for the most serious selenium toxicity outbreak that has occurred in the U.S. We quantified selenium concentrations in the misformulated supplement products, measured the temporal response in the nail biologic monitor, and associated exposure to self-reported selenosis symptoms. Subjects recruited through state health departments and referrals provided samples of the misformulated supplement products, exposure information, monthly toenail and or fingernail clippings or onycholysitic nail fragments, and listed their newly onset adverse health effects attributed to selenium toxicity. Ninety-seven subjects enrolled and submitted at least one test sample. Peak selenium concentrations (up to 18.3 and 44.1 μg/g for toenails and fingernails, respectively) were measured. Multiple samples (52 total) of all six recalled supplement lots were analyzed ranging from 22,300 to 32,200 μg selenium per daily dose. Average consumption was 30.9 ± 13.9 doses; 73 subjects provided follow-up data on selenosis symptoms at 2.50 ± 0.14 years. Nail samples accurately reflect exposure in this selenium toxicity outbreak, which resulted in long-term/permanent adverse health effects.
Collapse
Affiliation(s)
- John Steven Morris
- Research Reactor Center, University of Missouri, Columbia, MO 65211, USA; E-Mail:
- Division of Research Services, Truman Memorial Veterans Hospital, Columbia, MO 65211, USA
| | - Stacy B. Crane
- Research Reactor Center, University of Missouri, Columbia, MO 65211, USA; E-Mail:
| |
Collapse
|
35
|
Vinceti M, Crespi CM, Malagoli C, Del Giovane C, Krogh V. Friend or foe? The current epidemiologic evidence on selenium and human cancer risk. JOURNAL OF ENVIRONMENTAL SCIENCE AND HEALTH. PART C, ENVIRONMENTAL CARCINOGENESIS & ECOTOXICOLOGY REVIEWS 2013; 31:305-41. [PMID: 24171437 PMCID: PMC3827666 DOI: 10.1080/10590501.2013.844757] [Citation(s) in RCA: 64] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Abstract
Scientific opinion on the relationship between selenium and the risk of cancer has undergone radical change over the years, with selenium first viewed as a possible carcinogen in the 1940s then as a possible cancer preventive agent in the 1960s-2000s. More recently, randomized controlled trials have found no effect on cancer risk but suggest possible low-dose dermatologic and endocrine toxicity, and animal studies indicate both carcinogenic and cancer-preventive effects. A growing body of evidence from human and laboratory studies indicates dramatically different biological effects of the various inorganic and organic chemical forms of selenium, which may explain apparent inconsistencies across studies. These chemical form-specific effects also have important implications for exposure and health risk assessment. Overall, available epidemiologic evidence suggests no cancer preventive effect of increased selenium intake in healthy individuals and possible increased risk of other diseases and disorders.
Collapse
Affiliation(s)
- Marco Vinceti
- Environmental, Genetic and Nutritional Epidemiology Research Center (CREAGEN), University of Modena and Reggio Emilia, Modena, Italy
- Department of Diagnostic, Clinical Medicine and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy
| | - Catherine M. Crespi
- Department of Biostatistics, University of California Los Angeles Fielding School of Public Health, Los Angeles, California, USA
| | - Carlotta Malagoli
- Environmental, Genetic and Nutritional Epidemiology Research Center (CREAGEN), University of Modena and Reggio Emilia, Modena, Italy
- Department of Diagnostic, Clinical Medicine and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy
| | - Cinzia Del Giovane
- Department of Diagnostic, Clinical Medicine and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy
- Italian Cochrane Centre, University of Modena and Reggio Emilia, Modena, Modena, Italy
| | - Vittorio Krogh
- Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| |
Collapse
|
36
|
Iskandar AR, Liu C, Smith DE, Hu KQ, Choi SW, Ausman LM, Wang XD. β-cryptoxanthin restores nicotine-reduced lung SIRT1 to normal levels and inhibits nicotine-promoted lung tumorigenesis and emphysema in A/J mice. Cancer Prev Res (Phila) 2012; 6:309-20. [PMID: 23275008 DOI: 10.1158/1940-6207.capr-12-0368] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Nicotine, a large constituent of cigarette smoke, is associated with an increased risk of lung cancer, but the data supporting this relationship are inconsistent. Here, we found that nicotine treatment not only induced emphysema but also increased both lung tumor multiplicity and volume in 4-nitrosamino-1-(3-pyridyl)-1-butanone (NNK)-initiated lung cancer in A/J mice. This tumor-promoting effect of nicotine was accompanied by significant reductions in survival probability and lung Sirtuin 1 (SIRT1) expression, which has been proposed as a tumor suppressor. The decreased level of SIRT1 was associated with increased levels of AKT phosphorylation and interleukin (il)-6 mRNA but decreased tumor suppressor p53 and retinoic acid receptor (RAR)-β mRNA levels in the lungs. Using this mouse model, we then determined whether β-cryptoxanthin (BCX), a xanthophyll that is strongly associated with a reduced risk of lung cancer in several cohort studies, can inhibit nicotine-induced emphysema and lung tumorigenesis. We found that BCX supplementation at two different doses was associated with reductions of the nicotine-promoted lung tumor multiplicity and volume, as well as emphysema in mice treated with both NNK and nicotine. Moreover, BCX supplementation restored the nicotine-suppressed expression of lung SIRT1, p53, and RAR-β to that of the control group, increased survival probability, and decreased the levels of lung il-6 mRNA and phosphorylation of AKT. The present study indicates that BCX is a preventive agent against emphysema and lung cancer with SIRT1 as a potential target. In addition, our study establishes a relevant animal lung cancer model for studying tumor growth within emphysematous microenvironments.
Collapse
Affiliation(s)
- Anita R Iskandar
- Nutrition and Cancer Biology Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA 02111, USA
| | | | | | | | | | | | | |
Collapse
|
37
|
Abstract
The fraction of population that is elderly has been increasing, as has the consumption of vitamin/trace mineral supplements, which is now a multibillion dollar industry. Yet the rationale for such supplement intake by the majority may be questioned. Some of the current recommendations for micronutrient intake by the elderly are extrapolations from recommendations made for younger adults, whereas other recommendations are based on measurements of biochemical indices not proven to reflect a deficient level in the elderly. Suggestions that the elderly need more than the recommended daily allowances largely rest on the assumption that they should have biochemical indices similar to younger adults despite decreased energy intake with decreased physical and metabolic activities of the elderly. Although some individuals require supplementation because of problems with intake, absorption, or metabolism, there is little or no proof that boosting micronutrient intake above what can be achieved in well-balanced diets, some of which already contain fortified foods, will lead to a healthier outcome for most elderly individuals. There is not only the potential for unnecessary and occasionally harmful excess administered to some, but there is a cost that now runs in the billions of dollars and adds to the costs of covering multiple chronic disease conditions. Hence, some caution should be exercised in public health promulgations concerning routine use of supplements for those in this age group (>65 y of age) and of both sexes until more research establishes clear connections between the need for micronutrients and nutrient-related health in the elderly.
Collapse
Affiliation(s)
- Donald B McCormick
- Department of Biochemistry and Program in Nutrition and Health Sciences, Emory University, Atlanta, GA, USA.
| |
Collapse
|